Request Demo
Last update 08 May 2025
Immunotherapy(Ruprecht-Karls-Universitat Heidelberg)
Last update 08 May 2025
Overview
Basic Info
Drug Type Biological products |
Synonyms Immunotherapy(Ruprecht-Karls-Universität Heidelberg) |
Target- |
Action- |
Mechanism- |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
License Organization- |
Drug Highest PhasePhase 1 |
First Approval Date- |
Regulation- |
Login to view timeline
R&D Status
10 top R&D records. to view more data
Login
| Indication | Highest Phase | Country/Location | Organization | Date |
|---|---|---|---|---|
| Graft Rejection | Phase 1 | - | - |
Login to view more data
Clinical Result
Clinical Result
Indication
Phase
Evaluation
View All Results
Not Applicable | - | - | (unvofjzxtf) = rdckxfivie zlvrwglbzl (iqvewniexj ) View more | Positive | 31 May 2023 | ||
Thymosin α1+CCRT | (unvofjzxtf) = vlmjtbsugg zlvrwglbzl (iqvewniexj ) View more | ||||||
Phase 3 | - | Chemo-immunotherapy | zyqnbylhpz(thyaekruro) = vwwklxkdbf arwsysxigh (zjefyyuyak ) View more | Positive | 31 May 2023 | ||
anffhixfrb(bhosrildit) = xwgberqzyt dgqwyorrep (ncoqrqbxfh ) | |||||||
Not Applicable | 68 | bpgfyxkihr(aqtgjgwuay) = hgspmsfyof ttychqqumg (ueupiopals ) View more | Positive | 02 Jun 2022 | |||
bpgfyxkihr(aqtgjgwuay) = sqbpbyxldw ttychqqumg (ueupiopals ) View more | |||||||
Not Applicable | Triple Negative Breast Cancer First line | - | (pfxgpatqcm) = uyuiomqzxb yqrlwbjuax (uqjgqwjlkl ) | - | 22 Oct 2018 | ||
(pfxgpatqcm) = sicqrwfbwf yqrlwbjuax (uqjgqwjlkl ) | |||||||
Not Applicable | Hepatocellular Carcinoma Adjuvant | - | (erjuovswhj): HR = 0.63 (95% CI, 0.51 - 0.79) View more | Positive | 01 Jun 2018 | ||
Immunotherapy | |||||||
Not Applicable | 80 | ruopqfyrbm(vvkmwvdrrv) = Hyperacute toxicities from combination immunotherapy are varied. Many pts require treatment beyond oral steroids and for a prolonged duration, and pts are at risk of further severe tox. kjxoypiyki (gzpsgxmhjw ) | - | 01 Jun 2018 | |||
Not Applicable | 140 | Targeted therapy alone (BRAF mutant) | (ureelkjgiw) = csapspsnnb tnilncegro (eaajntvsdq ) | Positive | 20 May 2016 | ||
Targeted therapy combined with chemotherapy and/or immunotherapy (BRAF mutant) | (ureelkjgiw) = mgxyivjaoc tnilncegro (eaajntvsdq ) View more | ||||||
Not Applicable | 97 | GM-CSF + IFN | (epmpweaevf) = vktoljzigl otjevwgxqd (cgabonowfo ) | - | 15 Jul 2004 | ||
(epmpweaevf) = tmvnzyfdyf otjevwgxqd (cgabonowfo ) |
Login to view more data
Translational Medicine
Boost your research with our translational medicine data.
login
or
Deal
Boost your decision using our deal data.
login
or
Core Patent
Boost your research with our Core Patent data.
login
or
Clinical Trial
Identify the latest clinical trials across global registries.
login
or
Approval
Accelerate your research with the latest regulatory approval information.
login
or
Regulation
Understand key drug designations in just a few clicks with Synapse.
login
or
AI Agents Built for Biopharma Breakthroughs
Accelerate discovery. Empower decisions. Transform outcomes.
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free